Yungjin Pharm (003520) Fundamentals 2026 — Revenue Analysis | SniperIQ
Yungjin Pharm (003520) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩216.5B, trading at ₩1184.00 on the KSC. This SniperIQ fundamentals page covers Yungjin Pharm's valuation, profitability (net margin -1.4%), revenue (₩254.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yungjin Pharm's market cap?
Yungjin Pharm (003520) has a market capitalization of approximately ₩216.5B, trading at ₩1184.00 on the KSC. Market cap moves with the live share price.
What is Yungjin Pharm's P/E ratio?
Yungjin Pharm's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Yungjin Pharm?
Yungjin Pharm runs a net profit margin of -1.4%, a gross margin of 29.1%, and an operating margin of -0.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yungjin Pharm generate?
Yungjin Pharm reported revenue of ₩254.3B for fiscal year 2025, with net income of -₩228M and earnings per share (EPS) of -1.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yungjin Pharm pay a dividend?
Yungjin Pharm does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Yungjin Pharm financially healthy?
Yungjin Pharm carries a debt-to-equity ratio of 0.96x and a current ratio of 1.66x, with a market beta of 0.71. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yungjin Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yungjin Pharm (003520) the key facts are: market cap ₩216.5B, revenue ₩254.3B, 52-week range 1081-2320. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Yungjin Pharm's full fundamentals live
Get Yungjin Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.